aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.7653
-0.0507 (-6.21%)
At close: Dec 11, 2025, 4:00 PM EST
0.7618
-0.0035 (-0.46%)
Pre-market: Dec 12, 2025, 8:11 AM EST
aTyr Pharma Revenue
aTyr Pharma had revenue of $190.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $190.00K, down -19.15% year-over-year. In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$190.00K
Revenue Growth
-19.15%
P/S Ratio
394.68
Revenue / Employee
$2,923
Employees
65
Market Cap
74.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATYR News
- 22 hours ago - Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - GlobeNewsWire
- 4 days ago - aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR - PRNewsWire
- 4 days ago - ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile Corp
- 5 days ago - ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewsWire
- 7 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PRNewsWire
- 8 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR - GlobeNewsWire
- 8 days ago - ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewsWire
- 10 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile Corp